Beyond platelet functional testing: Value in the aggregate

Biomarkers in Medicine

Volumn 5, Issue 1, 2011, Pages 5-8

  Jakubowski, Joseph A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

ADP; clopidogrel; genomics; metabolism; P2Y12; pharmacokinetics; platelet testing; prasugrel; thienopyridines

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ELINOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; EDITORIAL; GENETIC SCREENING; HUMAN; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; POINT OF CARE TESTING; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; HUMANS; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 79951789750     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.11.5     Document Type: Editorial

References (21)

1. Price MJ, Barker CM: Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists. Biomarkers Med. 5(1), 43-51 (2011).
2. Gurbel PA, Bliden KP, Butler K et al.: Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120, 2577-2585 (2009).
3. Gurbel PA, Bliden KP, Antonino MJ et al.: The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J. Thromb. Haemost. 8, 43-53 (2010).
4. Niitsu Y, Jakubowski JA, Sugidachi A, Asai A: Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin. Thromb. Hemost. 31, 184-194 (2005). (Pubitemid 40605193)
5. Jakubowski JA, Winters KJ, Naganuma H, Walletin L: Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovas. Drug Rev. 25, 358-374 (2007).
6. Jakubowski JA, Riesmeyer JS, Close SL, Leishman AG, Erlinge D: TRITON and beyond: new insights into the profile of prasugrel. Cardiovasc. Ther. 29 (2011) (In Press).
7. Frelinger AL, Jakubowski JA, Li Y et al.: The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium, and aspirin. Thromb. Haemost. 98, 192-200 (2007). (Pubitemid 47074196)
8. Farid NA, Kurihara A, Wrighton SA: Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 50, 126-142 (2010).
9. Jakubowski JA, Payne CD, Li YG et al.: A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb. Haemost. 99, 215-222 (2007).
10. Jakubowski JA, Payne CD, Li YG et al.: The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb. Haemost. 99, 409-415 (2008). (Pubitemid 351230973)
11. Breet NJ, van Werkum JW, Bouman HJ et al.: Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303, 754-762 (2010).
12. Jernberg T, Payne CD, Winters KJ et al.: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27, 1166-1173 (2006).
13. Wiviott SD, Braunwald E, McCabe CH et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007). (Pubitemid 350106708)
14. Wiviott SD, Trenk D, Frelinger AL et al.: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The PRINCIPLE-TIMI 44 trial. Circulation 116, 2923-2932 (2007).
15. Angiolillo DJ, Saucedo JF, Deraad R et al.; SWAP Investigators: Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (Switching Anti Platelet) study. J. Am. Coll. Cardiol. 56, 1017-1023 (2010).
16. Michelson AD, Frelinger AL III, Braunwald E et al.: Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart J. 30, 1753-1763 (2009).
17. Mega JL, Close SL, Wiviott SD et al.: Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
18. Mega JL, Close SL, Wiviott SD et al.: Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119, 2553-2560 (2009).
19. Mega JL, Close SL, Wiviott SD et al.: Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376, 1312-1319 (2010).
20. Wrishko RE, Ernest CS 2nd, Small DS et al.: Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J. Clin. Pharmacol. 49, 984-998 (2009).
21. Small DS, Farid NA, Payne CD et al.: Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin. Pharmacokinet. 49, 777-798 (2010).